DNA encoding a soluble fragment of TRAIL polypeptide

Details DNA encoding a soluble fragment of TRAIL polypeptide DNA encoding a soluble fragment of TRAIL polypeptide

2011-07-05

2011-07-05

Mertz, Prema (Department: 1646)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C536S023500, C435S325000, C435S252300, C435S252800, C435S320100

Reexamination Certificate

active

07972812

ABSTRACT:
A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.

REFERENCES:
patent: 5512435 (1996-04-01), Renschler et al.
patent: 5716805 (1998-02-01), Srinivasan et al.
patent: 5876954 (1999-03-01), Perron et al.
patent: 6030945 (2000-02-01), Ashkenazi
patent: 6444640 (2002-09-01), Nagane et al.
patent: 6740739 (2004-05-01), Ashkenazi et al.
patent: 6746668 (2004-06-01), Ashkenazi
patent: 6998116 (2006-02-01), Ashkenazi
patent: 7285533 (2007-10-01), Ashkenazi
patent: 2002/0115613 (2002-08-01), Kumar
patent: 2007/0036782 (2007-02-01), Ashkenazi
patent: 2009/0162364 (2009-06-01), Ashkenazi
patent: WO-9518819 (1995-07-01), None
patent: WO-9725428 (1997-07-01), None
patent: WO-97/33899 (1997-09-01), None
patent: WO-9733899 (1997-09-01), None
patent: WO-9746686 (1997-12-01), None
patent: WO-99/07408 (1999-02-01), None
patent: WO-9907408 (1999-02-01), None
patent: WO-9936535 (1999-07-01), None
patent: WO-9948527 (1999-09-01), None
Banner et al., “Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation,”Cell73: 431-445, 1993.
Beers and Berkow, The Merck Manual of Diagnosis and Therapy, 17th edition, pp. 955-962 (1999).
Beers et al., The Merck Manual of Diagnosis and Therapy, 17th ed., pp. 986-995 (1999).
Bell, G.I. and Takeda, J., NCBI databank record, accession No. T10524, Jul. 28, 1993.
Belliveau et al., “Presence of the cytokine APO-2L (TRAIL), in the cerebrospinal fluid of multiple sclerosis patients,” Society for Neuroscience Abstracts 23(1-2). 1997; p. 2207.
Belliveau et al., “Presence of the cytokine, APO-2L (TRAIL), in the cerebrospinal fluid of multiple sclerosis patients,” Poster presented at the 27th Annual Meeting of the Society for Neuroscience, Oct. 25-30, 1997, New Orleans.
Berg et al. “Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L,” Cell Death and Differentiation 14:2021-2034 (2007).
Beutler and van Huffel, “Unraveling function in the TNF ligand and receptor families,”Science 264: 667-668, 1994.
Beutler B. and Cerami A., “Cachectin and tumour necrosis factor as two sides of the same biological coin,”Nature320: 584, 1986.
Bowie, et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,”Science247: 1306-1310, 1990.
Genexpress, NCBI databank record, accession No. Z36726, Aug. 18, 1994.
Goodwin et al., “Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor,”Eur. J. Immunol.23: 2631-2641, 1993.
Goodwin et al., “Study of the structure and function of Trail, a new member of the TNF ligand family,”Eur. Cytokine Network7(2): 166, 1996.
Gruss H.J. and Dower S.K., “Tumor Necrosis Factor Ligand Superfamily: involvement in the pathology of malignant lymphomas,”Blood85(12): 3378-3404, Jun. 15, 1995.
Hillier et al., NCBI databank record, accession No. R31020, Apr. 28, 1995.
Hillier et al., NCBI databank record, accession No. T82085, Mar. 10, 1995.
Hillier et al., NCBI databank record, accession No. T90422, Mar. 20, 1995.
Hollenbaugh et al., “Construction of immunoglobulin fusion proteins,”Current Protocols in Immunology, Supp. 4, 1992, 10.19.1-10.19.11.
Hoppe et al., “A parallel three stranded α-helical bundle at the nucleation site of collagen triple-helix formation,”FEBS Letters 344: 191-195, 1994.
Jo, M. et al., “Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand,”Nature Medicine6: 564-567, May 2000.
Kroemer, “The pharmacology of T cell apoptosis,”Adv. Immunol. 58: 211-296, 1995.
Landschultz, et al., “The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins,”Science240: 1759-1764, 1988.
Locksley et al., “The TNF and TNF receptor superfamilies: Integrating mammalian biology,” Cell 104: 487-501, 2001.
Marsters et al., “Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA,”Current Biology6(6): 750, 1996.
Menard et al., “A gliotoxic factor and multiple sclerosis,”J Neurological Sciences154: 209-221, 1998.
Mikayama et al., Proc. Natl. Acad. Sci. USA, 90:10056-10060 (1993).
Notice of Opposition to European Patent 0835305 titled “Cytokine that induces Apoptosis” (Immunex Corporation) filed by National University of Ireland, Galway, (2006).
O'Mahoney et al., “An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage,”J. Immunol. 151(9): 4847-4856, 1993.
Pitti et al., “Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family,”J. Biol. Chem. 271(22): 12687-12690, 1996.
Reiger, F. and J. Belliveau, report on research studies, in letter dated Aug. 31, 1999.
Rieger, R. et al., Glossary of Genetics and Cytogenetics, Fourth Ed., Springer-Verlag, pp. 16-19, 1976.
Sachs and Lotem, “Control of programmed cell death in normal and leukemic cells: new implications for therapy,”Blood82(1): 15-21, 1993.
Smith et al., “CD30 Antigen, a marker for Hodgkin's Lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF,”Cell73: 1349-1360, 1993.
Smith et al., “The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death,”Cell76: 959-962, 1994.
Smith et al., “Trail: a new member of the TNF ligand family that induces apoptosis,”Eur. Cytokine Network7(3): 429, 1996.
Suda et al., “Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family,”Cell75: 1169-1178, 1993.
Takahashi et al., “Human Fas ligand: gene structure, chromosomal location and species specificity,”International Immunol.6(10): 1567-1574, 1994.
Takeda et al., “A molecular inventory of human pancreatic islets: sequence analysis of 1000 cDNA clones,”Human Molecular Genetics2(11): 1793-1798, 1993.
Voet et al., Biochemistry, John Wiley & Sons, Inc. pp. 126-128 and 228-234 (1990).
Wang et al., “Molecular cloning of the complementary DNA for human tumor necrosis factor,”Science228:149, 1985.
Ware, et al., “Molecular cloning of the complementary DNA for human tumor necrosis factor,” Science 228:149, 1985.
Wiley et al., “Identification and characterization of a new member of the TNF family that induces apoptosis,”Immunity3:673-682, 1995.
Wong et al., “Antiviral properties of TNF,” inTumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, Raven Press, Ltd., New York, 1992, 371-381.

Affiliated with

Also associated with

Rating

DNA encoding a soluble fragment of TRAIL polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA encoding a soluble fragment of TRAIL polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding a soluble fragment of TRAIL polypeptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2669263